Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'

doi:10.1038/s41588-019-0509-5

Comment

. 2019 Oct;51(10):1427-1428.

doi: 10.1038/s41588-019-0509-5.

Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'

Mariano J Alvarez^{1

2}, Pengrong Yan³, Mary L Alpaugh^{3

4}, Michaela Bowden⁵, Ewa Sicinska⁶, Chensheng W Zhou⁶, Charles Karan¹, Ronald B Realubit¹, Prabhjot S Mundi^{1

7}, Adina Grunn¹, Dirk Jäger⁸, John A Chabot^{9

10}, Antonio T Fojo^{10

11}, Paul E Oberstein¹², Hanina Hibshoosh^{10

13}, Jeffrey W Milsom¹⁴, Matthew H Kulke¹⁵, Massimo Loda¹⁶, Gabriela Chiosis³, Diane L Reidy-Lagunes¹⁷, Andrea Califano^{18

19

20

21

22}

Affiliations

¹ Department of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.
² DarwinHealth Inc., New York, NY, USA.
³ Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Molecular and Cellular Biosciences, Rowan University, Glassboro, NJ, USA.
⁵ Department of Translational Medicine, Bristol-Meyers Squibb, Boston, MA, USA.
⁶ Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
⁷ James J. Peters Virginia Medical Center, Bronx, NY, USA.
⁸ Medical Oncology, National Center for Tumor Diseases Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
⁹ Department of Surgery, Columbia University Irvin Medical Center, New York, NY, USA.
¹⁰ Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
¹¹ Department of Medicine, Columbia University Irvin Medical Center, New York, NY, USA.
¹² Department of Medical Oncology, Perlmutter Cancer Center, New York, NY, USA.
¹³ Department of Pathology, Columbia University Irvin Medical Center, New York, NY, USA.
¹⁴ Colon and Rectal Surgery, Weill Cornell Medicine, New York, NY, USA.
¹⁵ Department of Hematology and Medical Oncology, Boston University Cancer Center, Boston, MA, USA.
¹⁶ Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
¹⁷ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁸ Department of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA. califano@cumc.columbia.edu.
¹⁹ Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.
²⁰ JP Sulzberger Columbia Genome Center, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.
²¹ Department of Biomedical Informatics, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.
²² Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.

PMID: 31548719
PMCID: PMC7256901
DOI: 10.1038/s41588-019-0509-5

Comment

Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'

Mariano J Alvarez et al. Nat Genet. 2019 Oct.

. 2019 Oct;51(10):1427-1428.

doi: 10.1038/s41588-019-0509-5.

Authors

Affiliations

¹ Department of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA.
² DarwinHealth Inc., New York, NY, USA.
³ Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Molecular and Cellular Biosciences, Rowan University, Glassboro, NJ, USA.
⁵ Department of Translational Medicine, Bristol-Meyers Squibb, Boston, MA, USA.
⁶ Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
⁷ James J. Peters Virginia Medical Center, Bronx, NY, USA.
⁸ Medical Oncology, National Center for Tumor Diseases Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
⁹ Department of Surgery, Columbia University Irvin Medical Center, New York, NY, USA.
¹⁰ Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
¹¹ Department of Medicine, Columbia University Irvin Medical Center, New York, NY, USA.
¹² Department of Medical Oncology, Perlmutter Cancer Center, New York, NY, USA.
¹³ Department of Pathology, Columbia University Irvin Medical Center, New York, NY, USA.
¹⁴ Colon and Rectal Surgery, Weill Cornell Medicine, New York, NY, USA.
¹⁵ Department of Hematology and Medical Oncology, Boston University Cancer Center, Boston, MA, USA.
¹⁶ Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
¹⁷ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁸ Department of Systems Biology, Columbia University Irvin Medical Center, New York, NY, USA. califano@cumc.columbia.edu.
¹⁹ Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.
²⁰ JP Sulzberger Columbia Genome Center, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.
²¹ Department of Biomedical Informatics, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.
²² Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA. califano@cumc.columbia.edu.

PMID: 31548719
PMCID: PMC7256901
DOI: 10.1038/s41588-019-0509-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests

M.J.A. is Chief Scientific Officer and an equity holder at DarwinHealth, Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. A.C. is a founder, equity holder, consultant and director of DarwinHealth, Inc. Columbia University is also an equity holder in DarwinHealth, Inc.

Comment on

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A. Alvarez MJ, et al. Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18. Nat Genet. 2018. PMID: 29915428 Free PMC article.
H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines.
Hofving T, Karlsson J, Nilsson O, Nilsson JA. Hofving T, et al. Nat Genet. 2019 Oct;51(10):1426-1427. doi: 10.1038/s41588-019-0490-z. Nat Genet. 2019. PMID: 31548718 No abstract available.

Cited by

Multifaceted modeling of small intestinal neuroendocrine tumors.
Andrews SG, Forsythe SD, Madigan JP, Sadowski SM. Andrews SG, et al. Endocr Oncol. 2024 Nov 20;4(1):e240038. doi: 10.1530/EO-24-0038. eCollection 2024 Jan 1. Endocr Oncol. 2024. PMID: 39649120 Free PMC article. Review.
Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
Briest F, Koziolek EJ, Albrecht J, Schmidt F, Bernsen MR, Haeck J, Kühl AA, Sedding D, Hartung T, Exner S, Welzel M, Fischer C, Grötzinger C, Brenner W, Baum RP, Grabowski P. Briest F, et al. Neoplasia. 2021 Jan;23(1):80-98. doi: 10.1016/j.neo.2020.11.004. Epub 2020 Nov 25. Neoplasia. 2021. PMID: 33246310 Free PMC article.
OncoLoop: A Network-Based Precision Cancer Medicine Framework.
Vasciaveo A, Arriaga JM, de Almeida FN, Zou M, Douglass EF, Picech F, Shibata M, Rodriguez-Calero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, Califano A, Abate-Shen C. Vasciaveo A, et al. Cancer Discov. 2023 Feb 6;13(2):386-409. doi: 10.1158/2159-8290.CD-22-0342. Cancer Discov. 2023. PMID: 36374194 Free PMC article.
A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection.
Laise P, Stanifer ML, Bosker G, Sun X, Triana S, Doldan P, La Manna F, De Menna M, Realubit RB, Pampou S, Karan C, Alexandrov T, Kruithof-de Julio M, Califano A, Boulant S, Alvarez MJ. Laise P, et al. Commun Biol. 2022 Jul 19;5(1):714. doi: 10.1038/s42003-022-03663-8. Commun Biol. 2022. PMID: 35854100 Free PMC article.
Preclinical Models of Neuroendocrine Neoplasia.
Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. Sedlack AJH, et al. Cancers (Basel). 2022 Nov 17;14(22):5646. doi: 10.3390/cancers14225646. Cancers (Basel). 2022. PMID: 36428741 Free PMC article. Review.

See all "Cited by" articles

References

1. Hofving T, Karlsson J, Nilsson O & Nilsson JA Nat Genet. 10.1038/s41588-019-0490-z (2019). - DOI - PubMed
1. Alvarez MJ et al. Nat. Genet 50, 979–989 (2018). - PMC - PubMed
1. Hofving T et al. Endocr. Relat. Cancer 25, X1–X2 (2018). - PMC - PubMed
1. Rajbhandari P et al. Cancer Discov. 8, 582–599 (2018). - PMC - PubMed
1. Califano A & Alvarez MJ Nat. Rev. Cancer 17, 116–130 (2017). - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Research Materials
- Cellosaurus - a cell line knowledge resource

[1] Hofving T, Karlsson J, Nilsson O & Nilsson JA Nat Genet. 10.1038/s41588-019-0490-z (2019). - DOI - PubMed

[2] Hofving T, Karlsson J, Nilsson O & Nilsson JA Nat Genet. 10.1038/s41588-019-0490-z (2019). - DOI - PubMed

[3] Alvarez MJ et al. Nat. Genet 50, 979–989 (2018). - PMC - PubMed

[4] Alvarez MJ et al. Nat. Genet 50, 979–989 (2018). - PMC - PubMed

[5] Hofving T et al. Endocr. Relat. Cancer 25, X1–X2 (2018). - PMC - PubMed

[6] Hofving T et al. Endocr. Relat. Cancer 25, X1–X2 (2018). - PMC - PubMed

[7] Rajbhandari P et al. Cancer Discov. 8, 582–599 (2018). - PMC - PubMed

[8] Rajbhandari P et al. Cancer Discov. 8, 582–599 (2018). - PMC - PubMed

[9] Califano A & Alvarez MJ Nat. Rev. Cancer 17, 116–130 (2017). - PMC - PubMed

[10] Califano A & Alvarez MJ Nat. Rev. Cancer 17, 116–130 (2017). - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'

Affiliations

Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials